Advertisement

Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington’s Disease

  • Scott Ayton
  • Peng Lei
  • Ambili T. Appukuttan
  • Thibault Renoir
  • Simote Foliaki
  • Feng Chen
  • Paul A. Adlard
  • Anthony J. Hannan
  • Ashley I. BushEmail author
Original Article

Abstract

There is currently no disease-modifying treatment for Huntington’s disease (HD), which is characterized by chorea motor impairment and cognitive decline. The zinc ionophore, PBT2, was previously shown to improve the phenotype of a HD mouse model and reported efficacy in certain cognitive tests in a phase II clinical trial in HD. Here we report that zinc deficiency is a feature of the hippocampus and cortex in the R6/1 mouse model of HD. Low cortical zinc has been shown to induce cognitive impairment, and indeed, dietary restriction of zinc in R6/1 mice was associated with cognitive impairment in the Y-maze, an exacerbated hippocampal long-term potentiation (LTP) deficit and reduction of AMPA receptors (and not other glutamatergic receptors). These data reveal the importance of zinc in maintaining brain function in HD.

Key Words

Huntington’s disease zinc cognition animal model 

Notes

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Funding Information

This study was supported by funds from the Australian National Health & Medical Research Council (NHMRC: APP1113686). The Florey Institute of Neuroscience and Mental Health recognizes support from the Victorian Government, in particular funding from the Operational Infrastructure Support Grant. No funder of this study had any role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Compliance with Ethical Standards

All animal experiments were approved by the Howard Florey Animal Ethics Committee (permit # 13-110 and 14-056) and were conducted in accordance with state law and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes as described by the National Health and Medical Research Council of Australia.

Disclosures

Dr. Bush is a shareholder in Prana Biotechnology Pty Ltd., Cogstate Pty Ltd., Eucalyptus Pty Ltd., Mesoblast Pty Ltd., Brighton Biotech LLC, Nextvet Ltd., Grunbiotics Pty Ltd., and Collaborative Medicinal Development LLC, and a paid consultant for Collaborative Medicinal Development. Dr. Adlard is a shareholder in, and consultant for, Prana Biotechnology Pty Ltd. The other authors declare that they have no competing interests.

Supplementary material

13311_2019_785_MOESM1_ESM.pdf (515 kb)
ESM 1 (PDF 514 kb)

References

  1. 1.
    MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–983.CrossRefGoogle Scholar
  2. 2.
    Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington’s disease. Nature reviews Neuroscience. 2013;14(10):708–721.CrossRefGoogle Scholar
  3. 3.
    Cherny RA, Ayton S, Finkelstein DI, Bush AI, McColl G, Massa SM. PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington’s Disease. J Huntingtons Dis. 2012;1(2):211–219.Google Scholar
  4. 4.
    Huntington Study Group Reach HDI. Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet neurology. 2015;14(1):39–47.CrossRefGoogle Scholar
  5. 5.
    Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. International review of neurobiology. 1989;31:145–238.CrossRefGoogle Scholar
  6. 6.
    Adlard PA, Parncutt JM, Finkelstein DI, Bush AI. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer’s disease? The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30(5):1631–1636.CrossRefGoogle Scholar
  7. 7.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.CrossRefGoogle Scholar
  8. 8.
    Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18(2):291–295.CrossRefGoogle Scholar
  9. 9.
    van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington’s disease. BMC neuroscience. 2008;9:34.CrossRefGoogle Scholar
  10. 10.
    Guyenet SJ, Furrer SA, Damian VM, Baughan TD, La Spada AR, Garden GA. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp. 2010(39).  https://doi.org/10.3791/1787.
  11. 11.
    Dure LSt, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington’s disease. Annals of neurology. 1991;30(6):785–793.CrossRefGoogle Scholar
  12. 12.
    Wright DJ, Gray LJ, Finkelstein DI, Crouch PJ, Pow D, Pang TY, et al. N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington’s disease. Human molecular genetics. 2016;25(14):2923–2933.Google Scholar
  13. 13.
    Frederickson CJ, Koh JY, Bush AI. The neurobiology of zinc in health and disease. Nature reviews Neuroscience. 2005;6(6):449–462.CrossRefGoogle Scholar
  14. 14.
    Sullivan JA, Zhang XL, Sullivan AP, Vose LR, Moghadam AA, Fried VA, et al. Zinc enhances hippocampal long-term potentiation at CA1 synapses through NR2B containing NMDA receptors. PloS one. 2018;13(11):e0205907.CrossRefGoogle Scholar
  15. 15.
    Anderson CT, Radford RJ, Zastrow ML, Zhang DY, Apfel UP, Lippard SJ, et al. Modulation of extrasynaptic NMDA receptors by synaptic and tonic zinc. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(20):E2705–14.CrossRefGoogle Scholar
  16. 16.
    Kambe T, Tsuji T, Hashimoto A, Itsumura N. The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. Physiological reviews. 2015;95(3):749–784.CrossRefGoogle Scholar
  17. 17.
    Bortolotto ZA, Fitzjohn SM, Collingridge GL. Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Current opinion in neurobiology. 1999;9(3):299–304.CrossRefGoogle Scholar
  18. 18.
    Takeda A, Sakurada N, Ando M, Kanno S, Oku N. Facilitation of zinc influx via AMPA/kainate receptor activation in the hippocampus. Neurochemistry international. 2009;55(6):376–382.CrossRefGoogle Scholar
  19. 19.
    Sensi SL, Yin HZ, Weiss JH. AMPA/kainate receptor-triggered Zn2+ entry into cortical neurons induces mitochondrial Zn2+ uptake and persistent mitochondrial dysfunction. The European journal of neuroscience. 2000;12(10):3813–3818.CrossRefGoogle Scholar
  20. 20.
    Yin HZ, Ha DH, Carriedo SG, Weiss JH. Kainate-stimulated Zn2+ uptake labels cortical neurons with Ca2+-permeable AMPA/kainate channels. Brain research. 1998;781(1–2):45–56.CrossRefGoogle Scholar
  21. 21.
    Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. The Journal of biological chemistry. 2002;277(9):7466–7476.CrossRefGoogle Scholar
  22. 22.
    Thomson SB, Leavitt BR. Transcriptional Regulation of the Huntingtin Gene. Journal of Huntington's Disease. 2018;7(4):289–296.CrossRefGoogle Scholar
  23. 23.
    Li Y, Kimura T, Huyck RW, Laity JH, Andrews GK. Zinc-induced formation of a coactivator complex containing the zinc-sensing transcription factor MTF-1, p300/CBP, and Sp1. Molecular and cellular biology. 2008;28(13):4275–4284.CrossRefGoogle Scholar
  24. 24.
    Aiba I, Hossain A, Kuo MT. Elevated GSH level increases cadmium resistance through down-regulation of Sp1-dependent expression of the cadmium transporter ZIP8. Molecular pharmacology. 2008;74(3):823–833.CrossRefGoogle Scholar
  25. 25.
    Qiu Y, Gao Y, Yu D, Zhong L, Cai W, Ji J, et al. Genome-wide analysis reveals zinc transporter ZIP9 regulated by DNA methylation promotes radiation-induced skin fibrosis via the TGF-β signaling pathway. Journal of Investigative Dermatology. 2019.  https://doi.org/10.1016/j.jid.2019.04.027.
  26. 26.
    Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease. Science. 2002;296(5576):2238–2243.CrossRefGoogle Scholar
  27. 27.
    Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice. Neuroscience. 2010;170(1):324–336.CrossRefGoogle Scholar
  28. 28.
    Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, et al. Mechanisms of copper ion mediated Huntington’s disease progression. PloS one. 2007;2(3):e334.CrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2019

Authors and Affiliations

  • Scott Ayton
    • 1
    • 2
    • 3
  • Peng Lei
    • 1
    • 2
    • 4
  • Ambili T. Appukuttan
    • 1
    • 2
  • Thibault Renoir
    • 2
  • Simote Foliaki
    • 1
    • 2
    • 3
  • Feng Chen
    • 1
    • 2
    • 3
  • Paul A. Adlard
    • 1
    • 2
    • 3
  • Anthony J. Hannan
    • 2
  • Ashley I. Bush
    • 1
    • 2
    • 3
    Email author
  1. 1.Melbourne Dementia Research CentreParkvilleAustralia
  2. 2.Florey Institute of Neuroscience and Mental HealthParkvilleAustralia
  3. 3.University of MelbourneParkvilleAustralia
  4. 4.Department of Neurology and State Key Laboratory of Biotherapy, West China HospitalSichuan University and Collaborative Center for BiotherapyChengduPeople’s Republic of China

Personalised recommendations